Whalesbook
Alembic Pharmaceuticals Limited has announced that Mr. Nilesh Wadhwa, its Head of Formulation Business Development, will resign from his position. His departure is effective March 31, 2026. The company formally acknowledged the resignation on December 31, 2025.
This marks another senior management transition for the Vadodara-based pharmaceutical firm. Recently, Mr. Prashant Khandelwal, Head-International Business Formulations, resigned effective December 1, 2025. In late 2025, Udit Amin was appointed Managing Director, while Malika Amin stepped down as CEO to continue as a director.
The role of Head of Formulation Business Development is critical for expanding Alembic's market reach and identifying new product opportunities. With operations in both domestic and international markets, investors will be watching for the company's appointment of a successor to drive its business development strategy.
The company is also addressing other matters, including tax assessment orders from Karnataka and Andhra Pradesh GST authorities and a legal dispute related to a solar PV system installation, though no immediate financial liability has been reported for the latter.
Alembic Pharmaceuticals operates within the competitive Indian pharmaceutical landscape alongside major players such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., and Zydus Lifesciences Ltd. These companies similarly navigate dynamic market conditions and regulatory environments.